Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597571 | 1.00 | BTK (0.55) | BTKCA1CA2CTSKGAA | |
| SCHEMBL10239204 | 1.00 | BTK (0.55) | BTKCA1CA2CTSKGAA | |
| SCHEMBL24874466 | 0.95 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| SCHEMBL13735251 | 0.95 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| SCHEMBL720530 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL8320677 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL720531 | 0.90 | CTSK (0.50) | BTKCA1CA2CTSKGAA | |
| SCHEMBL8220153 | 0.89 | BTK (0.54) | BTKCA1CA2CTSKGAA | |
| Ammonia Solution, Strong SCHEMBL28630271 | 0.86 | BTK (0.51) | BTKCA1CA2CTSKGAA | |
| SCHEMBL570801 | 0.83 | GAA (0.54) | BTKCA1CA2CTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600698-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| EP-4351552-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794543-A | Combination therapy with SETD2 inhibitors | EPIZYME股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2009021944-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025673-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| US-20080188490-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| CN-101160282-A | Acetylene derivative | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1877365-A1 | ACETYLENE DERIVATIVES | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877364-A1 | PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114262-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114260-A1 | PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | BTK 237/4885CA1 2823/4885CA2 2364/4885 |
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | BTK 3228/4885CA1 1163/4885CA2 2637/4885 |
| US-12600698-B2 | Kinase inhibitors | BTK, BMX, GSK3B | BTK 1/4885CA1 3514/4885CA2 1101/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BTK 128/4885CA1 3444/4885CA2 2494/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | BTK 237/4885CA1 2823/4885CA2 2364/4885 |
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | BTK 4/4885CA1 2640/4885CA2 2516/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | BTK 414/4885CA1 2121/4885CA2 1144/4885 |
| US-20080188490-A1 | Acetylene Derivatives | NAT1, CYP1A2, NAT10 | BTK 2147/4885CA1 3178/4885CA2 3068/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | BTK 1187/4885CA1 1405/4885CA2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.